[SCHEDULE 13D/A] Vor Biopharma Inc. SEC Filing
Amendment No. 3 to a Schedule 13D discloses that Reprogrammed Interchange LLC and Reid Hoffman reduced their combined beneficial stake in Vor BioPharma Inc. through multiple open-market sales. The reporting persons now report beneficial ownership of 33,928,487 shares (26.8% of the class). The amendment details sales from August 25 through September 11, 2025, that together total 5,045,614 shares sold in the referenced transactions, executed at weighted average prices mostly around $1.82–$2.12 per share. The filing states the sales were in open market transactions and that there are no related contracts or arrangements with respect to the issuer’s securities.
The amendment is a disclosure of significant share disposition by the reporting persons and confirms continued shared voting and dispositive power over the reported shares.
Modifica n. 3 a una Schedule 13D rivela che Reprogrammed Interchange LLC e Reid Hoffman hanno ridotto congiuntamente la loro partecipazione beneficiaria in Vor BioPharma Inc. tramite diverse vendite sul mercato aperto. I soggetti che riportano ora una titolarità di 33,928,487 azioni (26,8% della classe). La modifica dettaglia vendite compresi tra il 25 agosto e l'11 settembre 2025, che nel complesso ammontano a 5.045.614 azioni vendute nelle transazioni citate, eseguite a prezzi medi ponderati principalmente tra $1,82–$2,12 per azione. L'atto di deposito indica che le vendite sono avvenute in operazioni di mercato aperto e che non esistono contratti o accordi relativi ai titoli dell'emittente.
La modifica è una divulgazione di una significativa disposizione di azioni da parte dei soggetti che riportano e conferma il continuo potere di voto e di disposizione condiviso sulle azioni riportate.
Modificación n.º 3 de un Schedule 13D revela que Reprogrammed Interchange LLC y Reid Hoffman redujeron conjuntamente su participación beneficiosa en Vor BioPharma Inc. mediante varias ventas en el mercado abierto. Las personas que presentan ahora una titularidad de 33,928,487 acciones (26,8% de la clase). La enmienda detalla ventas desde el 25 de agosto hasta el 11 de septiembre de 2025, que en conjunto suman 5,045,614 acciones vendidas en las transacciones mencionadas, ejecutadas a precios medios ponderados principalmente entre $1,82–$2,12 por acción. El escrito indica que las ventas fueron en transacciones de mercado abierto y que no existen contratos o acuerdos relacionados con respecto a los valores del emisor.
La enmienda es una divulgación de una disposición significativa de acciones por parte de los informantes y confirma el continuo poder de voto y disposición compartido sobre las acciones reportadas.
Schedule 13D 제3 수정은 Reprogrammed Interchange LLC와 Reid Hoffman이 Vor BioPharma Inc.의 공동 유익 주식을 다수의 공개 시장 매도를 통해 축소했음을 밝힙니다. 보고 당사자들은 이제 33,928,487주(전체의 26.8%)의 유익한 소유를 보고합니다. 수정은 2025년 8월 25일부터 9월 11일까지의 매도를 자세히 설명하며, 합계 5,045,614주 판매가 관련 거래에서 이루어졌고 가중 평균가도 주로 $1.82–$2.12 사이로 나타납니다. 서류는 매도가 공개 시장 거래였으며 발행자의 증권에 관한 관련 계약이나 합의가 없다고 명시합니다.
이 수정은 보고 당사자들의 중요한 주식 처분에 대한 공시이며 보고된 주식에 대해 지속적인 공동 의결 및 처분 권한이 있음을 확인합니다.
L’amendement n° 3 à un Schedule 13D révèle que Reprogrammed Interchange LLC et Reid Hoffman ont réduit conjointement leur participation bénéficiaire dans Vor BioPharma Inc. par de multiples ventes sur le marché libre. Les personnes déclarante déclarent désormais une titularisation de 33 928 487 actions (26,8 % de la catégorie). L’amendement détaille des ventes du 25 août au 11 septembre 2025, qui totalisent 5 045 614 actions vendues dans les transactions citées, exécutées à des prix moyens pondérés principalement entre $1,82–$2,12 par action. Le dépôt indique que les ventes ont eu lieu dans des transactions sur le marché libre et qu’il n’existe ni contrats ni accords relatifs aux valeurs mobilières de l’émetteur.
Cet amendement constitue une divulgation d’une cession importante de parts par les personnes déclarante et confirme le pouvoir de vote et de disposition partagé de manière continue sur les actions déclarées.
Amendment Nr. 3 zu Schedule 13D offenbart, dass Reprogrammed Interchange LLC und Reid Hoffman ihre kombinierte begünstigte Beteiligung an Vor BioPharma Inc. durch mehrere Verkäufe am offenen Markt reduziert haben. Die meldenden Personen berichten nun über eine beherrschende Eigentümerschaft von 33.928.487 Aktien (26,8 % der Klasse). Die Änderung führt Verkäufe vom 25. August bis zum 11. September 2025 auf, die zusammen 5.045.614 Aktien verkauft umfassen, ausgeführt zu gewogenen Durchschnittspreisen, die größtenteils zwischen $1,82–$2,12 pro Aktie liegen. Die Einreichung gibt an, dass die Verkäufe in offenen Marktransaktionen stattfanden und dass es keine zugehörigen Verträge oder Vereinbarungen in Bezug auf Wertpapiere des Emittenten gibt.
Die Änderung ist eine Offenlegung einer bedeutenden Aktienveräußerung durch die meldepflichtigen Personen und bestätigt die fortdauernde gemeinsame Stimm- und Verfügungsgewalt über die gemeldeten Aktien.
التعديل رقم 3 على Schedule 13D يكشف أن Reprogrammed Interchange LLC وReid Hoffman خفّضا حصتهما المستفيدة الإجمالية في Vor BioPharma Inc. من خلال عدة مبيعات في السوق المفتوحة. يبلغ أصحاب البلاغ الآن عن ملكية مستفيدة قدرها 33,928,487 سهماً (26.8% من الفئة). يوضح التعديل تفاصيل مبيعات من 25 أغسطس حتى 11 سبتمبر 2025، والتي تبلغ مجتمعة 5,045,614 سهماً مباعة في المعاملات المشار إليها، التي نفذت بأسعار متوسطات موزونة تتراوح غالباً بين $1.82–$2.12 للسهم. يشير الإيداع إلى أن المبيعات تمت في معاملات السوق المفتوح وأنه لا توجد عقود أو ترتيبات ذات صلة بخصوص أوراق الشركة.
هذا التعديل هو كشف عن تقليص حصة كبيرة من قبل الأشخاص المبلغين ويؤكد الاستمرار في سلطة التصويت والتصرف المشتركة على الأسهم المعلنة.
Schedule 13D 的第3号修正案 揭示 Reprogrammed Interchange LLC 与 Reid Hoffman 通过多次公开市场出售，降低了他们在 Vor BioPharma Inc. 的合并有益股权。申报人现报告的受益所有权为 33,928,487 股（占该类别的 26.8%）。修正案详细说明自 2025 年 8 月 25 日至 9 月 11 日的出售，总计 5,045,614 股被出售，在相关交易中执行，成交加权平均价主要在 $1.82–$2.12/股。备案称这些出售属于公开市场交易，且发行业证券没有相关合同或安排。
该修正案是对报告人重要股权处置的披露，并确认对报导股权的持续共同投票权及处置权。
- Timely and detailed disclosure of open-market sales and remaining beneficial ownership, meeting Schedule 13D amendment requirements
- Continued substantial ownership retained: reporting persons still beneficially own 33,928,487 shares (26.8%)
- Material disposition of shares: combined sales of 5,045,614 shares across August 25–September 11, 2025, which may increase downward pressure on the stock
- Concentrated selling pattern in a short period with weighted average sale prices largely between $1.82 and $2.12, potentially signaling reallocation or liquidity-driven exits
Insights
TL;DR: Large open-market sales totaling over 5.0 million shares materially reduced the reporting persons' stake; this is a negative signal for shareholders.
The Schedule 13D/A documents concentrated, sequential open-market sales across late August and early September totaling 5,045,614 shares, executed at weighted average prices roughly between $1.82 and $2.12. The reporting persons still report shared beneficial ownership of 33,928,487 shares (26.8%), indicating they remain a substantial holder but have reduced exposure meaningfully in a short period. For investors, concentrated selling of this magnitude can increase supply pressure on the stock and may reflect liquidity needs or portfolio reallocation by the holders. The filing contains no statements of alternative purposes, arrangements, or contracts that would mitigate the market impact.
TL;DR: The reporting persons complied with disclosure obligations, but concentrated sales by a large holder raise governance and signaling concerns.
The amendment provides clear, itemized disclosure of open-market disposals across multiple dates and reports the remaining shared voting and dispositive power over the reported shares. From a governance perspective, maintaining transparency via timely amendments is positive; however, sustained selling by a major shareholder (over 5.0 million shares sold within the disclosed period) can alter shareholder composition and reduce the economic alignment of large holders. The filing makes no mention of related agreements or intent to change board representation or control, and no legal proceedings or arrangements are disclosed.
Modifica n. 3 a una Schedule 13D rivela che Reprogrammed Interchange LLC e Reid Hoffman hanno ridotto congiuntamente la loro partecipazione beneficiaria in Vor BioPharma Inc. tramite diverse vendite sul mercato aperto. I soggetti che riportano ora una titolarità di 33,928,487 azioni (26,8% della classe). La modifica dettaglia vendite compresi tra il 25 agosto e l'11 settembre 2025, che nel complesso ammontano a 5.045.614 azioni vendute nelle transazioni citate, eseguite a prezzi medi ponderati principalmente tra $1,82–$2,12 per azione. L'atto di deposito indica che le vendite sono avvenute in operazioni di mercato aperto e che non esistono contratti o accordi relativi ai titoli dell'emittente.
La modifica è una divulgazione di una significativa disposizione di azioni da parte dei soggetti che riportano e conferma il continuo potere di voto e di disposizione condiviso sulle azioni riportate.
Modificación n.º 3 de un Schedule 13D revela que Reprogrammed Interchange LLC y Reid Hoffman redujeron conjuntamente su participación beneficiosa en Vor BioPharma Inc. mediante varias ventas en el mercado abierto. Las personas que presentan ahora una titularidad de 33,928,487 acciones (26,8% de la clase). La enmienda detalla ventas desde el 25 de agosto hasta el 11 de septiembre de 2025, que en conjunto suman 5,045,614 acciones vendidas en las transacciones mencionadas, ejecutadas a precios medios ponderados principalmente entre $1,82–$2,12 por acción. El escrito indica que las ventas fueron en transacciones de mercado abierto y que no existen contratos o acuerdos relacionados con respecto a los valores del emisor.
La enmienda es una divulgación de una disposición significativa de acciones por parte de los informantes y confirma el continuo poder de voto y disposición compartido sobre las acciones reportadas.
Schedule 13D 제3 수정은 Reprogrammed Interchange LLC와 Reid Hoffman이 Vor BioPharma Inc.의 공동 유익 주식을 다수의 공개 시장 매도를 통해 축소했음을 밝힙니다. 보고 당사자들은 이제 33,928,487주(전체의 26.8%)의 유익한 소유를 보고합니다. 수정은 2025년 8월 25일부터 9월 11일까지의 매도를 자세히 설명하며, 합계 5,045,614주 판매가 관련 거래에서 이루어졌고 가중 평균가도 주로 $1.82–$2.12 사이로 나타납니다. 서류는 매도가 공개 시장 거래였으며 발행자의 증권에 관한 관련 계약이나 합의가 없다고 명시합니다.
이 수정은 보고 당사자들의 중요한 주식 처분에 대한 공시이며 보고된 주식에 대해 지속적인 공동 의결 및 처분 권한이 있음을 확인합니다.
L’amendement n° 3 à un Schedule 13D révèle que Reprogrammed Interchange LLC et Reid Hoffman ont réduit conjointement leur participation bénéficiaire dans Vor BioPharma Inc. par de multiples ventes sur le marché libre. Les personnes déclarante déclarent désormais une titularisation de 33 928 487 actions (26,8 % de la catégorie). L’amendement détaille des ventes du 25 août au 11 septembre 2025, qui totalisent 5 045 614 actions vendues dans les transactions citées, exécutées à des prix moyens pondérés principalement entre $1,82–$2,12 par action. Le dépôt indique que les ventes ont eu lieu dans des transactions sur le marché libre et qu’il n’existe ni contrats ni accords relatifs aux valeurs mobilières de l’émetteur.
Cet amendement constitue une divulgation d’une cession importante de parts par les personnes déclarante et confirme le pouvoir de vote et de disposition partagé de manière continue sur les actions déclarées.
Amendment Nr. 3 zu Schedule 13D offenbart, dass Reprogrammed Interchange LLC und Reid Hoffman ihre kombinierte begünstigte Beteiligung an Vor BioPharma Inc. durch mehrere Verkäufe am offenen Markt reduziert haben. Die meldenden Personen berichten nun über eine beherrschende Eigentümerschaft von 33.928.487 Aktien (26,8 % der Klasse). Die Änderung führt Verkäufe vom 25. August bis zum 11. September 2025 auf, die zusammen 5.045.614 Aktien verkauft umfassen, ausgeführt zu gewogenen Durchschnittspreisen, die größtenteils zwischen $1,82–$2,12 pro Aktie liegen. Die Einreichung gibt an, dass die Verkäufe in offenen Marktransaktionen stattfanden und dass es keine zugehörigen Verträge oder Vereinbarungen in Bezug auf Wertpapiere des Emittenten gibt.
Die Änderung ist eine Offenlegung einer bedeutenden Aktienveräußerung durch die meldepflichtigen Personen und bestätigt die fortdauernde gemeinsame Stimm- und Verfügungsgewalt über die gemeldeten Aktien.
FAQ
How many shares of VOR did the reporting persons report owning after this amendment?
How many Vor Biopharma (VOR) shares were sold in the disclosed transactions?
At what prices were the VOR shares sold in these transactions?
Were the reported sales open-market transactions or part of an agreement?
Who are the reporting persons named in the filing?
